ReviewBMC geriatrics2019
Giant cell arteritis: is the clinical spectrum of the disease changing?
Review in BMC geriatrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Establishing C-X-C motif chemokine receptor 4 as a novel imaging target in giant cell arteritis.Arthritis research & therapy · 2026Trial
- Atypical Oral Presentation of Giant Cell Arteritis With Subsequent Middle Cerebral Artery Involvement.Cureus · 2025Article
- Monocytes/Macrophages in Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease.Aging and disease · 2025Review
- Giant Cell Arteritis in the Third Decade of Life: A Case for Expanded Clinical Suspicion.Cureus · 2025Article
- Illness Burden and Unmet Patient Needs in Giant Cell Arteritis: Current State and Future Prospects.Open access rheumatology : research and reviews · 2025Review
- The spectrum of giant cell arteritis through a rheumatology lens.Eye (London, England) · 2024Review
- Cranial and extracranial manifestations of giant cell arteritis: a single-center observational study.Rheumatology international · 2024Observational
- Current Perspectives in Giant Cell Arteritis: Can We Better Connect Pathogenesis and Treatment?Medicina (Kaunas, Lithuania) · 2024Review
- Influenza A infection as a potential trigger of giant cell arteritis: A case report.SAGE open medical case reports · 2024Article
- Diagnostic delay in patients with giant cell arteritis: results of a fast-track clinic.Clinical rheumatology · 2024Article
- Relapse Risk and Safety of Long-Term Tocilizumab Use Among Patients With Giant Cell Arteritis: A Single-Enterprise Cohort Study.The Journal of rheumatology · 2023Article
- Atypical giant cell arteritis presentations diagnosed with FDG-18 whole body PET imaging.BMJ case reports · 2023Article
- Article
- Can a Giant Cell Arteritis (GCA) Risk Stratification Score Be Helpful in Clinical Practice?Cureus · 2022Article
- Giant Cell Arteritis: A Case-Based Narrative Review of the Literature.Current pain and headache reports · 2022Review
- Article
- Article
- Utilization of the Revised American College of Rheumatology (rACR) Scoring to Avoid Unnecessary Temporal Artery Biopsies-A Case Series.Medical sciences (Basel, Switzerland) · 2022Article
- Giant cell arteritis complicated by tongue necrosis and bilateral cerebellar ischaemic stroke.BMJ case reports · 2021Article
- Incidence, survival, and diagnostic trends in GCA across seven decades in a North American population-based cohort.Seminars in arthritis and rheumatism · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiant cell arteritis is a vasculitis of large and middle-sized arteries that affects patients aged over 50 years. It can show a typical clinical picture consisting of cranial manifestations but sometimes nonspecific symptoms and large-vessel involvement prevail. Prompt diagnosis and treatment is essential to avoid irreversible damage. DISCUSSION: There has been an increasing knowledge on the occurrence of the disease without the typical cranial symptoms and its close relationship and overlap with polymyalgia rheumatica, and this may contribute to reduce the number of underdiagnosed patients. Although temporal artery biopsy is still the gold-standard and temporal artery ultrasonography is being widely used, newer imaging techniques (FDG-PET/TAC, MRI, CT) can be of valuable help to identify giant cell arteritis, in particular in those cases with a predominance of extracranial large-vessel manifestations.
conclusionsGiant cell arteritis is a more heterogeneous condition than previously thought. Awareness of all the potential clinical manifestations and judicious use of diagnostic tests may be an aid to avoid delayed detection and consequently ominous complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.